Related Experiment Video
Updated: Aug 14, 2026
Identification of Novel CK2 Kinase Substrates Using a Versatile Biochemical Approach
Published on: February 21, 2019
Inspecting the structure-activity relationship of protein kinase CK2 inhibitors derived from tetrabromo-benzimidazole
Roberto Battistutta1, Marco Mazzorana, Stefania Sarno
1Department of Chemistry, University of Padua, via Marzolo 1, 35131 Padua, Italy. roberto.battistutta@unipd.it
Abstract:
CK2 is a very pleiotropic protein kinase whose high constitutive activity is suspected to cooperate to neoplasia. Here, the crystal structure of the complexes between CK2 and three selective tetrabromo-benzimidazole derivatives inhibiting CK2 with Ki values between 40 and 400 nM are presented. The ligands bind to the CK2 active site in a different way with respect to the parent compound TBB. They enter more deeply into the cavity, establishing halogen bonds with the backbone of Glu114 and Val116 in the hinge region. A detailed analysis of the interactions highlights a major role of the hydrophobic effect in establishing the rank of potency within this class of inhibitors and shows that polar interactions are responsible for the different orientation of the molecules in the active site.
Insights
Researchers elucidated the crystal structure of protein kinase CK2 complexes with novel inhibitors. These tetrabromo-benzimidazole derivatives show potent inhibition, offering insights into drug design for cancer therapy.
Area of Science:
- Biochemistry
- Structural Biology
- Medicinal Chemistry
Background:
- Protein kinase CK2 (Casein kinase 2) is a highly pleiotropic enzyme.
- Its constitutive activity is implicated in the development of various cancers (neoplasia).
- Targeting CK2 is a promising strategy for anti-cancer drug development.
Purpose of the Study:
- To determine the crystal structure of CK2 in complex with three novel selective inhibitors.
- To understand the binding interactions of these inhibitors within the CK2 active site.
- To provide insights for the rational design of more potent CK2 inhibitors.
Main Methods:
- X-ray crystallography was used to obtain the structures of CK2-inhibitor complexes.
- Enzyme inhibition assays were performed to determine the potency (Ki values) of the inhibitors.
- Structure-based analysis was employed to dissect inhibitor-target interactions.
Main Results:
- The crystal structures revealed how three tetrabromo-benzimidazole derivatives bind to the CK2 active site.
- These inhibitors exhibit Ki values in the nanomolar range (40–400 nM).
- Ligand binding involves deep cavity penetration, halogen bonds with Glu114/Val116, and significant hydrophobic and polar interactions.
Conclusions:
- The detailed structural analysis elucidates the molecular basis for CK2 inhibition by these benzimidazole derivatives.
- Hydrophobic effects are crucial for determining inhibitor potency, while polar interactions dictate binding orientation.
- These findings facilitate the design of next-generation CK2 inhibitors for potential therapeutic applications in oncology.
